Funders and Donors
The goal of JDRF CCTN is to implement studies and clinical trials to evaluate promising new therapies that will intervene in disease progression and/or improve the management of T1D and its complications. To this end, JDRF CCTN is partnering with leading investigators and institutions, with all partners working collaboratively toward this shared goal.
Some of JDRF CCTN's key partners are listed below:
In response to Ontario's economic challenges, Budget 2009 provided more than $1 billion over five years for a new southern Ontario development agency. The agency's programs will support economic and community development, innovation, and economic diversification, with contributions to communities, businesses and non-profit organizations. It will help workers, communities and businesses in southern Ontario position themselves to take advantage of opportunities, as economic growth recovers in Canada and around the world.
JDRF is the leading global organization focused on type 1 diabetes (T1D) research. Driven by passionate, grassroots volunteers connected to children, adolescents, and adults with the disease, JDRF is the largest charitable supporter of T1D research. The goal of JDRF is to improve the lives of all people affected by T1D by accelerating progress on the most promising opportunities for curing, better treating, and preventing the disease.
JDRF is the leading global organization focused on type 1 diabetes (T1D) research. JDRF’s goal is to progressively remove the impact of T1D from people’s lives until we achieve a world without T1D. JDRF collaborates with a wide spectrum of partners and is the only organization with the scientific resources, regulatory influence and a working plan to bring life-changing therapies from the lab to the community. As the largest charitable supporter of T1D research, JDRF is currently sponsoring $568 million in charitable research in 17 countries. For more information, please visit www.jdrf.org
Lilly has been a global leader in diabetes care since 1923, when we introduced the world’s first commercial insulin. Today we are building upon this heritage by working to meet the diverse needs of people with diabetes and those who care for them. Through research and collaboration, a broad and growing product portfolio and a continued determination to provide real solutions—from medicines to support programs and more—we strive to make life better all those affected by diabetes around the world. www.lilly.ca.
WB Family Foundation
In 2014, the W.B. Family Foundation generously donated $3 million to the CCTN. This funding allowed us to expand our clinical trial activity to three additional projects in Western Canada.